Werewolf Therapeutics shares surge 89.94% after hours as $33 million deal with EMD Serono brings fresh non-dilutive cash.

Werewolf Therapeutics shares surge 89.94% after hours as $33 million deal with EMD Serono brings fresh non-dilutive cash.

Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.